Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy

Journal of Interventional Medicine

Meng Niu¹  Fan Wang²  Hongbo Ni²  Jian Xue²  Ke Xu² 

[1] Corresponding author.;Department of Interventional Radiology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110000, China;

关键词: Hepatocellular carcinoma;    Locoregional therapy;    Immunotherapy;    Targeted therapy;    Combination therapy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Locoregional therapies (LRTs) of hepatocellular carcinoma (HCC) represented by ablation and TACE has become the main means for the clinical treatment of unresectable HCC. Among these, TACE is used throughout the stage Ib to IIIb of HCC treatment. In recent years, immunotherapy led by immune checkpoint inhibitors has become a hot direction in clinical research. At the same time, targeted drugs such as Sorafenib and Apatinib have played an important role in the treatment and complementary therapy of advanced HCC, and their clinical application has been quite mature. HCC is the sixth most common malignant tumor in the world. When it comes to its treatment, different therapies have different indications, and their individual efficacies are not satisfactory, which makes the exploration of the use of combination therapy in HCC treatment become a new trend. In this paper, the status of the three therapies and the progress of their combined application are briefly reviewed.

【 授权许可】

Unknown